Productive replication of human immunodeficiency virus type 1 (HIV-1) in brain macrophages and microglia is a critical component of viral neuropathogenesis. However, how virus-macrophage interactions lead to neurological disease remains incompletely understood. Possibly, a differential ability of virus to replicate in brain tissue macrophages versus macrophages in other tissues underlies HIV-1 neurovirulence. To these ends, we established systems for the isolation and propagation of pure populations of human microglia and then analyzed the viral life cycles of divergent HIV-1 strains in these cells and in cultured monocytes by using identical viral inocula and indicator systems. The HIV-1 isolates included those isolated from blood, lung tissue, cerebrospinal fluids (CSF), and brain tissues of infected subjects: HIV-1 ADA and HIV-1 89.6 (from peripheral blood mononuclear cells), HIV-1 DJV and HIV-1 JR-FL (from brain tissue), HIV-1 SF162 (from CSF), and HIV-1 BAL (from lung tissue). The synthesis of viral nucleic acids and viral mRNA, cytopathicity, and release of progeny virions were assessed. A significant heterogeneity among macrophage-tropic isolates for infection of monocytes and microglia was demonstrated. Importantly, a complete analysis of the viral life cycle revealed no preferential differences in the abilities of the HIV-1 strains tested to replicate in microglia and/or monocytes. Macrophage tropism likely dictates the abilities of HIV-1 to invade, replicate, and incite disease within its microglial target cells.
The human immunodeficiency virus (HIV) invades the central nervous system (CNS) early following viral infection but produces brain disease only years later. During the periods of progressive immunosuppression, from 15 to 25% of infected individuals develop cognitive and motor abnormalities referred to as the HIV type 1 (HIV-1)-associated dementia complex (ADC) (21, 44, 45) . Interestingly, and despite the significant neurological impairments observed in ADC, cells of neural origin (neurons, oligodendrocytes, and astrocytes) are rarely infected in affected brain tissue (47) . More than a decade of research led to a consensus that the clinical and neuropathologic abnormalities seen in ADC are likely a result of viral infection of mononuclear phagocytes (microglia and bloodderived brain macrophages) (27, 51, 56) . Microglia, the resident macrophages of the brain, were first described nearly six decades ago by del Rio Hortega (7, 8) , but as yet their functional significance in health and disease remains elusive. The role of mononuclear phagocytes in HIV neuropathogenesis is highlighted by HIV encephalitis (11, 55) , in which multinucleated giant cells (MGC) and perivascular macrophages are hallmarks of brain pathology (2, 10, 46) . Importantly, a recent study demonstrated that the number of immunocompetent brain macrophages is the best correlate for neurological disease in ADC (18) .
It is well established that all HIV-1 neuroinvasive isolates are macrophage tropic (15) . However, the degree of viral replication in brain tissue may not always predict disease progres-sion. Thus, it was hypothesized that a class of "neurotropic" HIV-1 isolates that preferentially infect microglia and incite disease exists (43, 50) . Infected microglial cells secrete neurotoxins that serve to amplify the pathological and clinical manifestations of ADC. Such a neuropathogenic mechanism is unique among neurovirological disorders. Indeed, for herpes simplex virus, cytomegalovirus, measles virus (subacute sclerosing panencephalitis), and other forms of viral encephalitis, productive viral replication occurs in neurons and is associated with direct neuronal cytopathicity (22) . Neuronal loss is caused as a direct consequence of viral infection. Alternatively, for parainfectious encephalomyelitis (mumps, measles, and rubella viruses), the virus produces neurological disease through autoimmune mechanisms (23) . For such diseases, virus cannot be demonstrated in the CNS yet an intense inflammatory reaction in the brain produces profound perivascular demyelination, presumably mediated by host immune responses elicited as a consequence of peripheral viral replication.
Whether or not HIV is truly neurotropic remains unresolved. A recent study of the viral determinants for simian immunodeficiency virus neurovirulence showed that although the envelope glycoprotein determined macrophage tropism, sequences from the transmembrane glycoprotein-encoding portion of the same gene along with nef conferred neurovirulence (35) . Such genetic signatures have not as yet been demonstrated conclusively for HIV (12, 28, 31, 43, 46, 49) . Nonetheless, if such subsets of HIV do exist and produce neurological impairments, perhaps by preferentially infecting microglia, such neurotropic viruses could have important implications in viral neuropathogenesis. In support of this concept, a recent report by Strizki and colleagues (50) demonstrated that specific HIV-1 strains show preferential abilities to replicate in microglia versus monocytes. However, the study examined only viral p24 production as a marker for HIV-1 replication. Quantitative assessments of the viral life cycle, beginning with the formation of proviral DNA and leading to the production of infectious progeny virions, had not been determined.
To investigate whether specific HIV-1 strains have a preferential ability to replicate in microglia, we quantitatively evaluated the viral life cycle in monocytes and microglia after virus exposure. We performed quantitative comparisons of the synthesis of viral nucleic acids in both cell types and determined productive replication by measuring reverse transcriptase (RT) activity in cell culture fluids. We show that a panel of viral isolates recovered from peripheral blood mononuclear cells (PBMCs), cerebrospinal fluid (CSF), and lung and brain tissues of infected patients exhibit differential levels of replication in monocytes that are identical to those observed in microglia.
MATERIALS AND METHODS
Reagents. Viral isolates HIV-1 JR-FL (29), HIV-1 BAL (14), HIV-1 89.6 (6), and HIV-1 SF162 (5) were obtained from the AIDS Research and Reference Reagent Program, National Institute of Allergy and Infectious Diseases. HIV-1 ADA was isolated from PBMC of a patient with AIDS as previously described (17) . HIV-1 DJV was obtained by monocyte cocultivation from brain tissue of a patient who died of dementia (20) . All viral strains were propagated on monocytes. HIV-1 LAI (41) and HIV-1 YU-2 (34) proviral plasmid DNAs were generous gifts from Michael Emerman and Beatrice Hahn, respectively. The isolates HIV-1 LAI and HIV-1 YU-2 were rescued with a 293T packaging system (40) . Briefly, episomal forms of the HIV-1 clones were used to transfect human kidney epithelial cells, the 293T cell line, in a transient-expression system. The resultant high-titer cell-free virions were used to infect monocytes or microglia. HIV-1 JR-FL , HIV-1 DJV , and HIV YU-2 were the neurotropic strains analyzed, as all were derived from brain tissue of infected subjects with HIV encephalitis. Table 1 provides a summary of the viral isolates used in this study. Antibodies to CD68 and HAM-56 (macrophages), glial fibrillary acidic protein (GFAP; astrocytes), and von Willebrand factor (endothelial cells) were purchased from Dako Corp., Carpinteria, Calif. The antibodies to neurofilament (NF), fluorescein isothiocyanate (FITC)-conjugated antibodies to mouse immunoglobulin G (IgG) F(abЈ) 2 fragments, and FITC-and rhodamine-conjugated antibodies to rabbit IgG F(abЈ) 2 fragments were procured from Boehringer Mannheim Corp., Indianapolis, Ind.
Isolation of microglia. Fetal brain tissue (gestational age, 14 to 20 weeks) was obtained from elective abortion procedures performed in full compliance with National Institutes of Health and University of Nebraska Medical Center ethical guidelines. The tissue was washed with cold Hanks balanced salt solution (Me-diaTech, Herndon, Va.) supplemented with Ca 2ϩ and Mg 2ϩ and then was digested with 0.25% trypsin (Sigma Chemical Co., St. Louis, Mo.) for 30 min at 37°C. Trypsin was neutralized with fetal bovine serum (FBS), and the tissue was further dissociated to obtain single-cell suspensions. The cells were resuspended in Dulbecco's modified Eagle's medium (DMEM) (Sigma) supplemented with a mixture containing 10% heat-inactivated FBS, 1,000 U of purified recombinant human macrophage colony stimulating factor (MCSF) per ml (a generous gift from Genetics Institute, Cambridge, Mass.), penicillin and streptomycin (50 g/ml), and 100 g of neomycin per ml. The mixed culture was maintained under 10% CO 2 for 7 days, and the medium was fully replaced to remove any cell debris. The microglia cells released with further incubation were collected and purified by preferential adhesion. Microglia were cultured as adherent monolayers at a density of 5 ϫ 10 4 cells/well in 96-well plates, and floating cells were removed after 4 h. The adherent microglia preparations (Ͼ98% pure) were identified by CD68 immunostaining. Replicate cultures were used for viral infections.
Isolation and cultivation of monocytes. PBMCs were obtained from HIV-1-, HIV-2-, and hepatitis B virus-seronegative donors by leukopheresis and were purified by countercurrent centrifugation to generate pure populations of monocytes (17) . Cell suspensions were found to be Ͼ98% pure monocytes by Wrightstaining, nonspecific esterase, granular peroxidase, and CD68 immunostaining assays. Cells were cultured in DMEM supplemented with 10% heat-inactivated pooled human serum-10 g of ciprofloxacin (Sigma) per ml-50 g of gentamicin (Sigma) per ml-1,000 U of MCSF per ml. All reagents were prescreened and found to be negative for endotoxin (Ͻ10 pg/ml; Associates of Cape Cod, Woods Hole, Mass.) and mycoplasma contamination (Gen-Probe II; Gen-Probe, San Diego, Calif.).
HIV-1 infection of monocytes and microglia. Monocytes and microglia were cultured on 96-well plates (Costar Corp., Cambridge, Mass.) at densities of 10 5 and 5 ϫ 10 4 cells/well, respectively, for 7 days prior to infection with HIV-1. The cell-free viral inoculum used for each experiment was standardized for all experiments by RT activity (2 ϫ 10 5 cpm/10 6 cells). Each experiment was performed in triplicate determinations. The culture medium was exchanged twice weekly, and samples were collected for RT activity measurement. RT activity was determined by incubating 10 l of sample with a reaction mixture consisting of 0.05% Nonidet P-40 (Sigma), 0.25 g of oligo(dT) per ml, 10 g of poly(A) (Pharmacia Fine Chemicals, Piscataway, N.J.) per ml, 150 mmol of KCl per liter, 15 mmol of MgCl 2 per liter, 5 mmol of dithiothreitol (Sigma) per liter, and [ 3 H]dTTP (2 Ci/mmol; Amersham Corp., Arlington Heights, Ill.) in Tris-HCl buffer (pH 7.9) for 24 h at 37°C. Radiolabeled nucleotides were precipitated on paper filters in an automatic cell harvester (Skatron, Sterling, Va.) with cold 10% trichloroacetate and 95% ethanol. The incorporated radioactivity was measured by liquid scintillation spectroscopy (26) . Adherent monolayers of monocytes and microglia were incubated with HIV-1 for 4 h at 37°C. The inoculum was withdrawn, and residual virus was washed off with fresh culture medium. Samples of culture supernatant were collected by medium exchange twice weekly for RT analysis. Viability of infected cells was measured by conversion of 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) to purple formazan.
PCR analysis of synthesis of viral nucleic acids. Monocytes (3 ϫ 10 6 cells/well) and microglia (5 ϫ 10 5 /well) were cultured on six-well plates (Costar Corp.) and infected with HIV-1 as described above. Prior to infection, the HIV-1 cell-free stocks were treated with DNase I for 30 min at 37°C (57) . At 8, 24, 48, 72, and 96 h postinfection, samples were collected for RT analysis and the residual medium was washed off with fresh phosphate-buffered saline (PBS; Sigma). The cells were then scraped in 1 ml of PBS. The resultant cell pellet was used for the extraction of cellular DNA with the Iso-quick nucleic extraction kit (ORCA Research Inc., Bothell, Wash.). The DNA was resuspended at a concentration of 10 4 cell equivalents/l. PCR was performed to identify early (primers to long terminal repeat [LTR] U3/R), intermediate (primers to pol I and J regions), and late (primers to LTR U3/gag) products of reverse transcription (57) . PCR primers to gag and nef regions of the viral genome were used to detect the episomal forms containing one and two LTRs (one-and two-LTR circles, respectively) (3, 4, 57) . Standard HIV-1 cDNAs were prepared by simultaneous amplification on serial twofold dilutions of DNA extracted from 8e5 cells that harbor defective HIV-1 proviruses (13) . Extrachromosomal one-LTR standards were generated by PCR on HIV-1 LAI -infected primary peripheral blood lymphocytes. Amplified products were hybridized to radiolabeled oligonucleotide probes and quantified on a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.).
Immunocytochemistry. Microglia were seeded on 8-mm-diameter chamber slides (Nunc Inc., Naperville, Ill.) and were cultured as described above. Cells were fixed in an ice-cold absolute acetone-methanol (1:1) mixture for 15 min at Ϫ20°C and then incubated with monoclonal antibodies (MAb) to CD68 or HAM-56 (at a dilution of 1:50) or to GFAP at a 1:100 dilution. Additional MAbs to HLA-DR, NF, CD14, and vimentin were from Boehringer Mannheim Corp. and were used at a 1:50 dilution. Antibodies to HIV-1 p24, galactocerebrocide (Gal-C; for oligodendrocytes), and von Willebrand factor were from Dako and were used at 1:5, 1:50, and 1:200 dilutions, respectively. Immunostaining was visualized by incubating the preparations with antibodies to mouse IgG F(abЈ) 2 fragments conjugated to FITC (at a 1:100 dilution) for p24, CD68, HLA-DR, CD14, and vimentin or antibodies to mouse IgM F(abЈ) 2 fragments conjugated to tetramethyl rhodamine isothiocyanate (TRITC; Boehringer) (at a 1:100 dilution) for HAM-56. Anti-rabbit IgG F(abЈ) 2 fragments conjugated to FITC (for GFAP) and rhodamine (for Gal-C and von Willebrand factor) were used at a 1:100 dilution. Antigen-reactive cells were viewed on a Nikon Microphot-FXA microscope (Nikon, Tokyo, Japan).
Electron microscopy. Microglia were placed on 12-mm-diameter coverslips (10 5 cells/coverslip) and cultured as described above. After viral infection, cells were fixed at days 7 and 21 postinfection with 2.5% glutaraldehyde, washed with cacodylate buffer, postfixed in 1% osmium tetroxide, and then dehydrated and embedded in LX 112 (Ladd Research Industries, Burlington, Vt.). Ultrathin sections were stained with uranyl acetate and lead citrate and then examined on a Philips EM 410 electron microscope (Eindhoven, The Netherlands) as previously described (37) .
RESULTS
Characterization of primary human fetal microglia. Detailed morphological and immunocytochemical characterizations of purified microglia cells were performed. The microglia were collected as a nonadherent layer from the mixed brain cell cultures and seeded on chamber slides as adherent cells. The microglia differentiated with time from an ameboid form and then developed processes that extended to several times the size of their initial small oval cell bodies ( Fig. 1A and D, respectively). Cultured microglia were stained with antibodies to cell-specific markers for macrophages (CD68 and HAM-56) ( Fig. 1A and B ), for astrocytes (GFAP) (Fig. 1H ), for endothelial cells (von Willebrand factor), for oligodendrocytes (Gal-C), and for neurons (NF) (data not shown) to establish purity. The cells were Ͼ98% pure on the basis of these characteristics. Double immunostaining with HAM-56 and GFAP showed that only HAM-56-positive cells were present in the culture and that none of the cells reacted with GFAP ( Fig. 1G and H). Double immunostaining with HLA-DR, a marker for cell activation, and HAM-56 showed that the percentage of HLA-DR-and HAM-56-double-positive cells was low (Ͻ25%) and that the cells expressed HLA-DR weakly ( Fig. 1E and F). This result was distinct from that previously reported by Lee et al. (33) , demonstrating that cultured fetal microglia were highly positive for HLA-DR. Staining for vimentin, a marker for cytoskeletal proteins, clearly showed the cell bodies and unique processes of microglial cells (Fig. 1D) . Interestingly, about 50% of the microglial cells were immunoreactive for CD14, the receptor for bacterial lipopolysaccharide (36) , and a marker believed to distinguish adult monocytes from microglia (52, 53) .
Comparative analysis of HIV-1 ADA infection of monocytes and microglia. With the establishment of highly purified human microglia, we compared levels of viral infection by using a prototypic macrophage-tropic viral strain, HIV-1 ADA . The accumulations of viral nucleic acids by PCR in monocytes and microglia infected with equivalent viral inocula were determined. The results are shown in Fig. 2 . The use of zidovudine (AZT) served as an internal control. In cells treated with AZT, intermediate and late products of reverse transcription were not detected. The viral DNA products identified in the HIV-1 ADA -inoculated cultures represent only de novo HIV-1 DNA synthesis. In both monocytes and microglia both intermediate and late products were detected at 8 h postinfection (Fig. 2) . The episomal forms of the viral nucleic acids (one-LTR circles) were also observed in monocytes and microglia at 8 h postinfection. As the episomal forms of the viral DNA indicate the completion of viral nucleic acid synthesis and the successful nuclear import across the nuclear membrane, our data show that under the culture conditions used, both monocytes and microglia support a complete cycle of synthesis of viral DNA, as early as 8 h after viral exposure. The experiment was re-peated for three individual donors for monocytes and microglia, and similar results were obtained. The ratios of early, intermediate, and late products of viral cDNA synthesis to a mitochondrial gene (the internal control for extraction of extrachromosomal DNA) were also determined, and similar kinetics were observed for all products of HIV-1 proviral DNA synthesis (data not shown). The peak accumulations of late products were at 48 h postinfection for monocytes ( Fig. 2) and microglia. Late-product accumulation reached a peak at 48 h and did not increase significantly thereafter.
We next examined the replication profiles of HIV-1 ADA in monocytes and microglia over a period of 3 to 4 weeks ( Fig. 3A  and B, respectively) . As virus-induced cytopathicity could affect the levels of virus produced, we also examined the viability of cells at specific times during the course of infection ( Fig. 3C and D). Both monocytes and microglia supported productive replication of HIV-1 ADA weeks after virus exposure. At days 14 and 21 postinfection, there was significant cell death observed for both cell types, and the RT production subsequently decreased. This experiment was repeated with three separate donors of microglia and was performed with three or more replicates. Thus, the synthesis of HIV-1 proviral DNA in monocytes and microglia infected with HIV-1 ADA occurs at equivalent rates and both cell types support productive viral replication.
Morphological, ultrastructural, and immunocytochemical studies of HIV-1 ADA -infected monocytes and microglia. Morphological and immunocytochemical characterizations of HIV-1 ADA -infected monocytes and microglia were performed. HIV-1 infection of microglia caused the fusion of individual cells and the formation of multinucleated syncytia, similar to infection of monocytes ( Fig. 4) (5) . The cytopathic effects were virtually indistinguishable in monocytes and microglia despite the fact that uninfected microglia bear longer processes and are bipolar compared to ameboid monocytes with relatively short processes.
By transmission electron microscopy (TEM), microglia cells showed typical ultrastructural features of fully differentiated macrophages, with well-developed cisternae of the endoplasmic reticulum, prominent Golgi apparatus, numerous elongated mitochondria, lysosomes, lipid droplets, vacuoles, and intermediate cytoplasmic filaments (Fig. 4C ). Most of the microglial phagosomes contained dense products of myelin degradation. The cells had long cytoplasmic processes and tightly contacted one another, forming gap junctions. The cytoplasmic membranes of the microglia were uneven with conspicuous filopodia. Typical cytopathic effects (in MGC) following viral infection were seen by TEM (Fig. 4D ). Such cells with several nuclei showed the same ultrastructural characteristics as uninfected cells, including numerous phagosomes with myelin remnants. In addition, typical mature and immature lentiviral particles in association with cytoplasmic vacuoles or cell membranes ( Fig. 4E and F) were detected.
Immunocytochemical evaluation of monolayer cultures of microglia infected with HIV-1 ADA showed that Ͼ50% of cells were consistently HIV-1 p24 positive 7 days after infection ( Fig. 4I ). MGC double immunoreactive for CD68 and HAM-56 were seen ( Fig. 4G and H) . Cells obtained from multiple donors (eight in all) of varying gestational ages (15 to 20 weeks) were cultured and infected on a routine basis and yielded similar results in terms of purity, morphology, and susceptibility to infection with HIV-1 ADA .
Analysis of viral DNA synthesis in monocytes and microglia infected with a panel of HIV-1 isolates.
An analysis of HIV-1 ADA -infected monocytes and microglia showed that there were no easily detectable differences in the two cell types with regard to the cell's ability to support productive viral replication. To expand upon these observations, we investigated the The synthesis of early, intermediate, and late products of reverse transcription and the presence of episomal forms of the viral nucleic acids were determined to assess successful nuclear import of the preintegration complex of HIV-1 proviral DNA. As shown with HIV-1 ADA , in cells treated with AZT, intermediate and late products were not detected. This was consistent for all isolates. Thus, the products identified in the monocyte cultures inoculated with HIV-1 represent de novo synthesis. In monocytes, both intermediate and late products were detected as early as 8 h postinfection for HIV-1 BAL , HIV-1 DJV , HIV-1 SF162 , HIV-1 JR-FL , and HIV-1 89.6 ( Fig. 5A, B , and C). HIV-1 late products were not observed in HIV-1 LAI -infected monocytes (Fig. 5C ). The episomal forms of the viral nucleic acids containing one LTR were detected in monocytes at 24 h postinfection for all macrophage-tropic strains (Fig. 5 ). HIV-1 YU-2 showed results similar to those illustrated for HIV-1 BAL and HIV-1 DJV (data not shown). Analysis of viral mRNA was performed in infected monocytes by techniques described previ- ously for in situ hybridization (16, 39) , and similar trends were observed (data not shown).
Next, the accumulations of viral nucleic acids in microglia infected with HIV-1 BAL , HIV-1 DJV , HIV-1 89.6 (Fig. 6A) , HIV-1 JR-FL , and HIV-1 SF162 (Fig. 6B) were determined. There was considerable accumulation of the late products of HIV-1 proviral DNA (identified by using LTR U3/gag regions) in microglia for all isolates. The trend was similar to that observed in virus-infected monocytes. The accumulation of episomal forms of the viral nucleic acids containing one LTR was detected at 72 h in microglia for both HIV-1 JR-FL and HIV-1 SF162 . As the episomal forms of viral DNA indicate completion of viral nucleic acid synthesis and successful nuclear import, the data show that with comparable levels of virus inocula both microglia and macrophages support a complete cycle of viral DNA synthesis. The extrachromosomal forms of viral cDNA containing two LTRs, which are low-abundance circle forms of the viral DNA (two-LTR circle), were also detected in microglia for both HIV-1 JR-FL and HIV-1 SF162 as early as 24 h postinfection (Fig. 6) . In monocytes the two-LTR circle forms were detected at 48 h postinfection (Fig. 5 ). For quantitative comparisons the ratios of the late products of reverse transcription to that of a mitochondrial gene were also calculated, and these ratios also reflected significant differences between viral strains (a range of 0.01 [for HIV-1 SF162 ] to 0.04 [for HIV-1 ADA ]). In addition, the kinetics of HIV-1 RT products was evident for all isolates used, as reflected by an increase in the early, intermediate, and late products with prolonged postinfection time points. These were observed for all viral isolates (data not shown). Moreover, the differences in the levels of productive infection between the isolates were also evident. HIV-1 DJV , HIV-1 BAL , HIV-1 JR-FL , and HIV-1 SF162 rapidly complete their viral life cycles in both monocytes and microglia. The rates of synthesis of proviral DNA in microglia infected with HIV-1 BAL , HIV-1 DJV , HIV-1 JR-FL , HIV-1 SF162 , and HIV-1 89.6 are comparable to those observed in monocytes.
Analysis of progeny virion production in monocytes and microglia infected with a panel of HIV-1 isolates. The production of progeny virions was measured by determining RT activity in culture fluids following HIV-1 infection in monocytes and microglia. Figure 7 shows the kinetics of productive replication of the panel of HIV-1 isolates. All macrophage-tropic strains productively infected both microglia and monocytes, albeit at different levels. HIV-1 LAI did not give rise to any productive infection. Lee and colleagues (32) showed that HIV-1 IIIB , when used at a high multiplicity of infection, led to infection of microglia. However, we did not find this for HIV-1 LAI , consistent with previous reports concerning T-tropic isolates (54) . More importantly, the pattern of the level of viral replication was identical for monocytes and microglia. HIV-1 ADA , HIV-1 DJV , and HIV-1 BAL elicited very high levels of productive infection in monocytes ( Fig. 7A and B ) and microglia ( Fig. 7C and D) . HIV-1 SF162 and HIV-1 89.6 gave incrementally reduced RT activity levels. HIV-1 YU-2 , a molecular clone directly obtained from infected brain tissue, also elicited very high levels of progeny virus production in both microglia and monocytes (data not shown). HIV-1 YU-2 was rescued in a high-efficiency packaging cell system (34, 40) and was used directly for infection. The levels of virus produced were higher for monocytes than for microglia, including HIV-1 YU-2 . HIV-1 SF162 and HIV-1 89.6 both reached peak RT activity later in microglia (day 40 and day 32, respectively). A similar result was seen in monocytes, as peak RT values were obtained on days 25 and 27, respectively. However, in general, peak RT values were delayed in microglia compared to monocytes. One-way analysis of group variance for both microglia and monocytes showed that the differences within the strain groups were sig- nificant (P Ͻ 0.0001). There was clear consistency for viral strains in both microglia and monocytes. The viabilities of the infected cells at specific time intervals after viral exposure were also similar for monocytes and microglia ( Fig. 8 ). HIV-1 DJV was highly cytopathic and led to significant cell death after 14 days of infection in both monocytes ( Fig. 8A) and microglia (Fig. 8B ). HIV-1 89.6 was the least cytopathic in both cell types. Interestingly, there was also consistency in the cytopathic effects observed in monocytes and microglia. These data demonstrate a heterogeneity among macrophage-tropic HIV-1 strains for infection of monocytes and microglia. HIV-1 ADA , HIV-1 DJV , and HIV-1 BAL were highly productive in both cell types while HIV-1 89.6 was significantly less so. HIV-1 LAI did not lead to productive viral replication in either monocytes or microglia. For each of the strains tested both cell types were equally susceptible to viral replication.
DISCUSSION
In this study we investigated whether the susceptibility to HIV-1 infection differed between primary human microglia and monocytes. Such differences, if found, could reflect a neurotropic potential for HIV-1. We first established highly purified and well-characterized microglia systems and studied HIV-1 replication at three different stages of the viral life cycle. These included the synthesis of viral DNA and viral mRNA (data not shown) and progeny virion production as indicated by RT activity in culture supernatants. From all the data taken together, we found that there was no significant difference in the susceptibilities of the two cell types to HIV-1 infection. Thus the ability of a given isolate to infect microglia or monocytes may not be generally utilized as a signature to distinguish between neurovirulent and macrophage-tropic viral strains. Prior studies suggested that qualitative, not quantitative, properties of HIV-1 mainly determine clinical differences between demented and nondemented patients (24) . A report by Strizki et al. (50) suggested that there is preferential HIV-1 infection of microglia for select viral strains. However, if such a finding were to be made for a small percentage of viral variants, it is unlikely to be a generalized observation to explain neurovirulent HIV-1 phenotypes. The ability of HIV-1 to produce disease within the CNS likely reflects multiple properties of virushost interactions that include but are not limited to host genetic properties, the degree of immunosuppression, immunologic factors (inside and outside the brain), the integrity of the blood-brain barrier, the presence of opportunistic infections, and the virulence of the viral strain(s) that affects the CNS, including the host cell range of the virus. The Strizki findings may have added relevance to HIV neuropathogenesis in the developed CNS, because the microglia obtained in their work were from mature brain specimens.
Given their functional and morphological plasticity (25) , microglia may play a unique role in HIV neuropathogenesis. The question as to whether microglia differ functionally from monocytes is unresolved. This question arises from the common origin of the two cell types. Despite their residence in the brain, microglia cells originate outside the CNS and migrate into the CNS in late embryonic life. It has also been previously demonstrated that microglia tropism maps at a region of HIV-1 env that similarly controls macrophage tropism (48) . Initial reports showed that fetal microglia obtained from firsttrimester tissue specimens were refractory to infection with HIV-1 (42); however, it was later shown that cultured microglia from second-trimester tissue and also adult microglia can be infected with macrophage-tropic but not lymphocyte celltropic isolates (54) . Subsequently, two groups have shown that at high infectivity doses, microglia cells can be susceptible to infection with lymphocyte cell-tropic isolates but are subject to donor variation (32, 50) . We did not find any infection of microglia with lymphocyte-tropic isolate HIV-1 LAI at a viral inoculate level equivalent to those for other isolates. Importantly, donor-to-donor variations were also not demonstrated. The data support the notion that macrophage and microglial tropisms for HIV-1 are similar.
HIV-1 is selectively localized within perivascular and infiltrated parenchymal blood-derived macrophages and microglia (9, 30, 51) , suggesting a hematogenous entry of the virus to the brain. Our data also suggest that it is the macrophage, rather than the viral isolate, that regulates penetration by HIV-1 into the CNS. The sequestration of virus in mononuclear phagocytes is a reservoir for HIV-1. The evolution of quasispecies of virus could occur separately within the CNS. The fact that there exists genetic variation in different HIV-1 isolates obtained from different patients and from the same individual is consistent with this hypothesis (19) . However, when HIV-1 isolates originally obtained from brain tissue or blood were compared, no significant difference in the comparative infectivity in microglia and monocytes was found.
An important issue for this work is that we utilized primary fetal microglia as target cells for HIV-1 infection. It is possible that fetal cells behave differently from cultured adult microglia. Indeed, the developing CNS is more susceptible to HIV-1 infection than the adult CNS (21) . Future studies in which adult and fetal microglia are compared (side by side) for viral infection may prove helpful in elucidating the unique abilities that fetal brain tissue has for HIV-1 infection and for eliciting neurological disease.
The presence of molecular variants of the virus is a reflection of the fact that retroviral RT does not have any proofreading function. For HIV-1 there is a potential change of nucleotides at a rate of one for every 10,000 bp. That would bring about one base substitution per genome in every replication cycle (38) . Studies comparing sequences of HIV-1 isolates from the brain and blood show that the envelope region of HIV-1 sequesters such mutations, indicating selection pressures. There are some conserved elements identified in the V3 loop of isolates derived from brains of demented patients compared to the consensus sequence shown by Korber et al., LaRosa et al., Power et al., and Shimizu et al. (28, 31, 43, 49) . This suggests a potential overlapping pathway for selection of neurovirulent isolates in different individuals. The importance of the V3 loop sequences in determining tropism is controversial (46) , as recently it was demonstrated that the residues originally thought to be critical for neurovirulence were also found in the majority of nondemented patient samples. Also, all of the brain-derived isolates lacked the proline residue at position 305, described initially by di Stefano et al. and Power et al. (12, 43) .
Thus, the issue of HIV-1 neurovirulence has been controversial. Needless to say, there is evidence to suggest that it is the qualitative property of the virus that determines disease progression in patients. However, there have not been any consistent data regarding a particular molecular property of the virus to assign a signature for neurovirulence. We suggest that it is the onset of the immune functions elicited by infection of microglia by certain isolates, as distinct from those elicited by infection of monocytes, that may be the basis for clinical differences of disease progression. It is generally accepted that the myriad of pathological manifestations of HIV-1 infection result from the interplay of molecules mediating intercellular interactions between infected microglia and macrophages, astrocytes, oligodendrocytes, and neurons, more specifically through the elaboration of various cytokines and potential neurotoxins (1, 15, 45) . Clearly, the network of microglia in the brain and their close proximity to the other neural elements make them central candidates for the differential immunemediated manifestations of HIV-1-induced neurological disease.
